the methods of Group II are very closely related to the implants of Group I and it is believed that it would be most efficient and correct to examine both groups at the same time, especially as the relevant prior art will likely be the same for both.

Consequently, it is urged that Group II not be restricted.

With respect to the requirement of election of species in Claims 9, 10 and 24 to 32, the species where at least two components of the implant are combined in separate pellets under Claim 10 is elected. This species falls under the subject matter claimed in Claims 10 and 24 to 32, although it is noted that the subject matter of many of these claims is generic to both species.

With respect to the other requirement of election of species of Claims 8, 11, 12, 14 to 18, 22, 23 and 29 to 31, it is noted that there are species and subspecies in certain cases within the subject matter. The requirement with respect to claims 30 and 31 is not understood.

If a growth stimulating agent (see Claim 2) must be selected then an estradiol compound, including estradiol, estradiol benzoate and zeranol is chosen. Of the claims subject to election of species, estradiol compounds are found in Claims 8, 14, 16, 18 and 23.

If a supplemental agent (see Claim 3) must be selected, then estrus suppressing compositions are selected which are called for in Claims 11 and 12.

If a parasiticide (see Claim 6) must be chosen, then ivermectin is selected which is called for in Claims 8, 22 and 29.

If an estrus suppressing composition (see Claim 11) must be chosen, then melengestrol acetate is selected and is found in Claim 12.

If a gonadotropin (see Claim 17) must be chosen, then · luteinizing hormone and commercial analogs thereof are chosen which is found in Claim 18.

The above is believed to fully respond to the requirements of the action. The Examiner is invited to contact the

Dale C. Kenison

undersigned by telephone, if prosecution of this application can be expedited thereby.

Respectfully Submitted,

John C. McMahon

Reg. No. 29,415

Attorney

JCM:kdc PO Box 30069 Kansas City, Missouri 64112

Phone:

(816) 531-3470

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on October 24, 2001.

Dale C. Kenison (Applicant)

Ву

October 24, 2001

(Date of Signature)